Bullish Moving Averages
16
Bearish Moving Averages
0
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
5430.00Today’s High
5589.0052W low
3125.0052W High
7221.00Open Price
5444.00Prev. Close
4928.0500Volume
17670.00Value
98152432.50Fundamentals
Market Cap Cr
13886.90
Price to Earnings
99.70
Price to Book Value
23.60
Dividend Yield
0.30
PE to Growth
3.70
Op Revenue TTM Cr
1197.03
Net Profit TTM Cr
139.30
Cash From Operating Activity Cr
58.29
Return on Equity %
16.86
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
29 Apr, 2024
58.6
Week
48.3
Month
64.3
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
5524.58
PIVOT
First Resistance
5619.17
Second Resistance
5683.58
Third Resistance
5778.17
First Support
5460.17
Second Support
5365.58
Third Support
5301.17
Relative Strength Index
63.18
Money Flow Index
64.55
MACD
23.67
MACD Signal
-15.2
Average True Range
154.48
Average Directional Index
19.63
Rate of Change (21)
9.29
Rate of Change (125)
21.13
Commodity Channel Index
192.4
Williams %R
-8.7
BETA
1 Month
1.11
3 Month
0.81
1 Year
0.39
3 Year
0.18
PRICE CHANGE ANALYSIS
↑ 7.03%
1 Week
Low
High
5192.35
5589
↑ 4.25%
1 Month
Low
High
5039
5595.85
↓ -11.85%
3 Months
Low
High
4785
7220.95
↑ 17.85%
6 Months
Low
High
4510
7220.95
↑ 74.22%
1 Year
Low
High
3125
7220.95
| Indicator | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 315.45 | 319.44 | 303.57 | 292.70 | 257.00 | 242.92 | 236.45 | 235.65 | 205.86 | 200.55 | 178.30 | |
| Operating Expenses Qtr | 290.73 | 258.31 | 228.22 | 224.85 | 213.22 | 195.40 | 204.37 | 194.00 | 185.86 | 179.79 | 159.77 | |
| Operating Profit Qtr | 15.06 | 52.76 | 67.25 | 59.85 | 36.59 | 40.72 | 27.96 | 37.96 | 14.67 | 17.92 | 15.63 | |
| EBIDT Qtr Cr | 24.72 | 77.56 | 75.35 | 27.62 | 43.79 | 47.52 | 32.08 | 41.64 | 20.00 | 20.76 | 18.53 | |
| Depreciation Qtr | 3.70 | 3.67 | 3.80 | 4.25 | 4.13 | 3.29 | 4.59 | 4.41 | 3.51 | 4.28 | 4.76 | |
| Net Profit Qtr | 15.80 | 52.37 | 53.86 | 17.27 | 29.30 | 32.56 | 20.15 | 27.98 | 11.42 | 11.95 | 10.24 | |
| Basic EPS Qtr | 6.32 | 20.95 | 21.54 | 6.91 | 11.72 | 13.03 | 8.06 | 11.19 | 4.57 | 4.78 | 4.10 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 1029.07 | 820.36 | 826.40 | 844.80 | 744.58 | |
| Operating Expenses Annual Cr | 837.85 | 719.42 | 678.09 | 711.11 | 656.99 | |
| Operating Profit Annual | 165.12 | 86.18 | 135.47 | 120.70 | 71.30 | |
| Operating Profit Margin Annual % | 16.05 | 10.51 | 16.39 | 14.29 | 9.58 | |
| Total Expenses Annual Cr | 854.74 | 737.32 | 699.31 | 730.83 | 671.91 | |
| EBIDT Annual Cr | 191.22 | 100.94 | 148.31 | 133.69 | 87.59 | |
| EBIDT Annual margin % | 18.58 | 12.30 | 17.95 | 15.83 | 11.76 | |
| Depreciation | 16.26 | 16.95 | 20.13 | 18.58 | 14.92 | |
| PAT Before ExtraOrdinary Items Annual Cr | 99.29 | 61.60 | 93.30 | 72.21 | 54.45 | |
| Net Profit Annual | 99.29 | 61.60 | 93.30 | 72.21 | 54.45 | |
| Basic EPS Annual | 39.70 | 24.60 | 37.30 | 28.90 | 21.80 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 588.69 | 511.39 | 456.17 | 364.44 | 300.80 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 12.25 | 12.52 | 15.04 | 14.68 | 2.02 | |
| Total Current Liabilities Annual Cr | 383.93 | 332.65 | 303.50 | 327.24 | 258.98 | |
| Total Capital Plus Liabilities Annual Cr | 984.87 | 856.56 | 774.71 | 706.36 | 561.80 | |
| Fixed Assets Annual | 70.19 | 76.69 | 84.98 | 95.77 | 81.73 | |
| Total Non Current Assets Annual | 149.40 | 150.89 | 155.95 | 164.04 | 157.08 | |
| Total Current Assets Annual | 835.47 | 705.67 | 618.76 | 542.32 | 404.72 | |
| Total Assets Annual | 984.87 | 856.56 | 774.71 | 706.36 | 561.80 | |
| Contingent Liabilities plus Commitments Annual Cr | 132.28 | 124.60 | 89.17 | 69.19 | 32.57 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 58.29 | 100.80 | 104.78 | 87.42 | 54.98 | |
| Cash from Investing Activity Annual | 18.11 | 4.74 | 173.03 | -170.80 | 4.28 | |
| Cash from Financing Annual Activity | -24.48 | -9.46 | -8.97 | -6.36 | 0.00 | |
| Net Cash Flow Annual | 51.92 | 96.08 | 268.84 | -89.74 | 59.26 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 235.48 | 204.56 | 182.47 | 145.78 | 120.32 | |
| ROE Annual % | 16.86 | 12.04 | 20.45 | 19.81 | 18.10 | |
| ROCE Annual % | 29.11 | 16.03 | 27.20 | 30.36 | 23.99 | |
| Total Debt to Total Equity Annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EBDIT Annual Margin % | 19.06 | 12.52 | 18.22 | 16.07 | 12.02 |
| Indicator | Graph |
|---|---|
| Total Qtr Revenue cr | |
| Operating Expenses Qtr | |
| Operating Profit Qtr | |
| EBIDT Qtr Cr | |
| Depreciation Qtr | |
| Net Profit Qtr | |
| Basic EPS Qtr |
| Indicator | Graph |
|---|---|
| Total Revenue Annual | |
| Operating Expenses Annual Cr | |
| Operating Profit Annual | |
| Operating Profit Margin Annual % | |
| Total Expenses Annual Cr | |
| EBIDT Annual Cr | |
| EBIDT Annual margin % | |
| Depreciation | |
| PAT Before ExtraOrdinary Items Annual Cr | |
| Net Profit Annual | |
| Basic EPS Annual |
| Indicator | Graph |
|---|---|
| Total ShareHolders Funds Annual | |
| Minority Interest Liability Annual Cr | |
| Total Non Current Liabilities Annual Cr | |
| Total Current Liabilities Annual Cr | |
| Total Capital Plus Liabilities Annual Cr | |
| Fixed Assets Annual | |
| Total Non Current Assets Annual | |
| Total Current Assets Annual | |
| Total Assets Annual | |
| Contingent Liabilities plus Commitments Annual Cr |
| Indicator | Graph |
|---|---|
| Cash from Operating Activity Annual | |
| Cash from Investing Activity Annual | |
| Cash from Financing Annual Activity | |
| Net Cash Flow Annual |
| Indicator | Graph |
|---|---|
| Book Value Per Share Annual | |
| ROE Annual % | |
| ROCE Annual % | |
| Total Debt to Total Equity Annual | |
| EBDIT Annual Margin % |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| SHIVANI TEJAS TRIVEDI | 2.43 | 74540669 | - | - |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| AstraZeneca Pharmaceuticals AB | 75 | 74540651 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| NIPPON LIFE INDIA TRUSTEE LTD - VARIOUS SCHEMES | 2.88 | 74540654 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| TEJAS BHALCHANDRA TRIVEDI | 2.72 | 74540668 |
| SHIVANI TEJAS TRIVEDI | 2.43 | 74540669 |
| MINAXI BHALCHANDRA TRIVEDI | 1.84 | 74540670 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Jul 14, 2023 | 16 | FINAL | Jul 14, 2023 | Equity Share |
| Jul 07, 2022 | 8 | FINAL | Jul 08, 2022 | Equity Share |
| Aug 18, 2021 | 2 | INTERIM | Aug 20, 2021 | Equity Share |
| Aug 20, 2020 | 2 | INTERIM | Aug 21, 2020 | Equity Share |
| Aug 20, 2019 | 1 | INTERIM | Aug 21, 2019 | Equity Share |
| Jul 09, 2012 | 3.5 | FINAL | - | Equity Share |
| Jul 07, 2011 | 10 | FINAL | - | Equity Share |
| May 06, 2010 | 10 | FINAL | - | Equity Share |
| Apr 29, 2009 | 15 | FINAL | - | Equity Share |
| Apr 11, 2008 | 15 | FINAL | - | Equity Share |
| Mar 22, 2007 | 12 | INTERIM | Mar 24, 2007 | Equity Share |
| Apr 12, 2006 | 20 | FINAL | - | Equity Share |
| Mar 18, 2005 | 50 | FINAL | - | Equity Share |
| Apr 16, 2004 | 3.9 | FINAL | - | Equity Share |
| Apr 17, 2003 | 3.7 | FINAL | - | Equity Share |
| May 15, 2002 | - | FINAL | - | Equity Share |
| Jun 18, 2001 | - | FINAL | - | Equity Share |
| Aug 11, 2000 | - | FINAL | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|---|---|
| Jun 15, 2006 | 10:2 | 2006-06-22 |
| Ex-Date | Purpose | Notes |
|---|---|---|
| Feb 08, 2024 | Quarterly Results | - |
| Nov 09, 2023 | Quarterly Results | - |
| Aug 14, 2023 | Quarterly Results | - |
| May 30, 2023 | Audited Results & Dividend | - |
| Feb 10, 2023 | Quarterly Results | - |
| Nov 11, 2022 | Quarterly Results | - |
| Aug 08, 2022 | Quarterly Results | - |
| May 26, 2022 | Audited Results & Final Dividend | - |
| Feb 08, 2022 | Quarterly Results | - |
| Nov 09, 2021 | Quarterly Results | - |
| Aug 09, 2021 | Quarterly Results & Interim Dividend | - |
| May 25, 2021 | Audited Results | - |
| Feb 08, 2021 | Quarterly Results | - |
| Nov 05, 2020 | Quarterly Results | - |
| Aug 10, 2020 | Quarterly Results & Interim Dividend | - |
| May 18, 2020 | Audited Results | - |
| Feb 03, 2020 | Quarterly Results | - |
| Nov 11, 2019 | Quarterly Results | - |
| Aug 07, 2019 | Quarterly Results & Interim Dividend | - |
| May 24, 2019 | Audited Results | - |
| Feb 06, 2019 | Quarterly Results | - |
| Nov 13, 2018 | Quarterly Results | - |
| Aug 13, 2018 | Unaudited Financial Results | - |
| May 21, 2018 | Audited Results | - |
| Feb 05, 2018 | Quarterly Results | - |
| Nov 06, 2017 | Quarterly Results | - |
| Aug 08, 2017 | Quarterly Results | - |
| May 09, 2017 | Audited Results | - |
| Feb 02, 2017 | Quarterly Results | - |
| Dec 02, 2016 | Others | Mr. Rajesh Marwaha, Chief Financial Officer of the Company hasbeen inducted into the board as Additional and Whole-time Director. His profile is attached. |
| Nov 11, 2016 | Quarterly Results | - |
| Aug 09, 2016 | Quarterly Results | - |
| May 25, 2016 | Audited Results | - |
| Feb 06, 2016 | Quarterly Results & Others | The Board of Directors approved the re-appointment of Mr. Sanjay Murdeshwar as Managing Director of the Company for a period of 3 years, to be effective from May 02, 2016. |
| Dec 02, 2015 | Others | Decided to close the Active Pharmaceutical Ingredient Unit (API Unit) situated at 12th Mile on Bellary Road,Venkatala, Yelahanka, Bangalore - 560063. |
| Nov 06, 2015 | Quarterly Results & Others | The Board appointed Ms. Claire-Marie O' Grady as Director of the Company in the vacancy caused by the resignation of Ms. Rebekah Martin with immediate effect. |
| Aug 04, 2015 | Quarterly Results | - |
| May 27, 2015 | Audited Results | - |
| Feb 11, 2015 | Quarterly Results | - |
| Nov 03, 2014 | Quarterly Results | - |
| Aug 12, 2014 | Quarterly Results | - |
| May 30, 2014 | Audited Results | - |
| May 05, 2014 | Others | To consider seeking approval of shareholders of the Company through Postal Ballot, for the voluntary delisting proposed by AstraZeneca Pharmaceuticals AB Sweden,Promoter of the company. |
| Apr 15, 2014 | Others | To consider for the voluntary delisting proposed by AstraZeneca Pharmaceuticals Promoter of the Company, in terms of Securities and Exchange Board of India, through Postal Ballot. |
| Mar 15, 2014 | Others | To consider the voluntary delisting proposal from AstraZeneca Pharmaceuticals AB, Sweden in terms of their letter dated March 01, 2014 at the meeting of the BOD of the Company held on March 15,2014. |
| Mar 05, 2014 | Others | - |
| Feb 10, 2014 | Quarterly Results | - |
| Nov 11, 2013 | Quarterly Results | - |
| Aug 13, 2013 | Quarterly Results | - |
| May 21, 2013 | Audited Results | - |
| May 06, 2013 | Others | - |
| May 02, 2013 | Quarterly Results | - |
| Feb 06, 2013 | Quarterly Results | - |
| Nov 07, 2012 | Quarterly Results | - |
| Aug 10, 2012 | Quarterly Results | - |
| May 11, 2012 | Audited & Quarterly Results | - |
| Feb 02, 2012 | Quarterly Results | - |
| Nov 10, 2011 | Quarterly Results | - |
| Aug 08, 2011 | Quarterly Results | - |
| Jun 14, 2011 | Others | inter alia, to consider and approve the proposal of straightening of land boundaries of factory with IDL Industries Ltd. |
| May 13, 2011 | Audited Results & Dividend | Fifteen Months. |
| Feb 08, 2011 | Quarterly Results | - |
| Oct 27, 2010 | Quarterly Results | - |
| Jul 27, 2010 | Quarterly Results & Others | For seeking the consent / approval of the Shareholders of the Company through postal ballot to the delisting proposal initiated by AstraZeneca Pharmaceuticals, AB, Sweden, promoter of the Company. |
| Jul 09, 2010 | Others | The Board has deferred the decision on delisting proposal initiated by AstraZeneca Pharmaceuticals AB Sweden, promoter of the Company. |
| Jun 29, 2010 | Voluntary Delisting of Shares | To make a voluntary delisting offer to the public Shareholders of the Co. in accordance with the SEBI (DES) Regulations, 2009 with a view to delist the Equity Shares from BSE, NSE & BgSE. |
| Apr 27, 2010 | Others | The Board has appointed Ms. Anita Zutshi as the Chief Financial Officer of the Company. |
| Apr 26, 2010 | Quarterly Results | - |
| Mar 25, 2010 | Others | 1. Proposal to augment the Co's Tablet manufacturing plant and facility involving an estimated aggregate outlay of Rs. 70 Crs. 2. Appointment of Mr. Luigi Felice La Corte, as an Additional Director. |
| Feb 23, 2010 | Audited Results, Dividend & Others | The Board has approved the change in the accounting year of the Company from "January-December" to "April-March" & Recommended a Dividend of Rs. 10/- per Equity Share of face value of Rs. 2/- each. |
| Oct 27, 2009 | Quarterly Results | - |
| Jul 27, 2009 | Quarterly Results | - |
| Apr 23, 2009 | Quarterly Results | - |
| Feb 18, 2009 | Audited Results & Dividend | - |
| Oct 23, 2008 | Quarterly Results | - |
| Jul 29, 2008 | Quarterly Results | - |
| Apr 28, 2008 | Quarterly Results | - |
| Feb 25, 2008 | Audited Results & Dividend | - |
| Oct 26, 2007 | Quarterly Results | - |
| Jul 26, 2007 | Quarterly Results | - |
| Apr 30, 2007 | Quarterly Results | - |
| Mar 17, 2007 | Interim Dividend | To consider the approval of the revised Audited Accounts for the financial year ended December 31, 2006, after incorporating necessary changes as to the revocation of recommended dividend & others. |
| Feb 23, 2007 | Accounts & Dividend | - |
| Oct 28, 2006 | Quarterly Results | - |
| Sep 08, 2006 | Issue of fully paid bonus debentures | Inter alia, to consider a proposal for issue by the Company of secured fully paid bonus debentures from its General Reserve in terms of a Scheme of Arrangement between the Company and its Shareholders |
| Aug 28, 2006 | Issue of fully paid bonus debentures | To consider a proposal for issue by the Company of secured fully paid bonus debentures from its General Reserve in terms of a Scheme of Arrangement between the Company and its Shareholders. (deferred) |
| Jul 28, 2006 | Quarterly Results | - |
| May 09, 2006 | Sub Division of Equity shares | - |
| Apr 29, 2006 | Quarterly Results | - |
| Feb 23, 2006 | Accounts & Dividend | - |
| Oct 20, 2005 | Quarterly Results | (Revised) |
| Aug 24, 2005 | Accounts | - |
| Apr 27, 2005 | Quarterly Results | - |
| Feb 16, 2005 | Accounts & Dividend | (Revised) |
| Oct 30, 2004 | Quarterly Results | - |
| Aug 16, 2004 | Quarterly Results | - |
| May 31, 2004 | Quarterly Results | (Revised) |
| Apr 21, 2004 | Others | Mr. Bhasker V. Iyer was appinted as an additional Director and Managing Director w.e.f. 06-05-2004. |
| Mar 04, 2004 | Others | Astra Pharmaceuticals AB(APAB) a promoter of the company, held 56.50% of the voting share capital of the company in March, 2002. |
| Feb 24, 2004 | Dividend & Accounts | - |
| Nov 26, 2003 | Quarterly Results | - |
| Aug 26, 2003 | Quarterly Results | - |
| Apr 28, 2003 | Quarterly Results | - |
| Feb 27, 2003 | Dividend, Accounts & Quarterly Results | - |
| Oct 29, 2002 | Quarterly Results | - |
| May 28, 2002 | Quarterly Results | - |
| Mar 14, 2002 | Accounts & Dividend (9 months) | - |
| Oct 17, 2001 | Quarterly Results | - |
| Jul 30, 2001 | Quarterly Results | - |
| Jul 19, 2001 | Quarterly Results | (Cancelled) |
| May 17, 2001 | Qtr Results, Dividend & Accounts | - |
| Jan 18, 2001 | Quarterly Results | - |
| Oct 31, 2000 | Quarterly Results | - |
| Jul 12, 2000 | Quarterly Results | - |
| Mar 30, 2000 | Interim Dividend | - |
| Jan 29, 2000 | Quarterly Results | - |
| Jan 19, 2000 | Quarterly Results | - |
| Oct 22, 1999 | Quarterly Results | - |
| Jul 21, 1999 | Quarterly Results | - |
| Apr 20, 1999 | Quarterly Results | - |
| Jan 28, 1999 | Quarterly Results | - |
| Oct 27, 1998 | Quarterly Results | - |
| Jul 28, 1998 | Quaterly Results | - |
| Jun 26, 1998 | Accounts & Dividend | - |
| May 27, 1998 | Half Yearly Results | - |
| Nov 11, 1997 | Half Yearly Results | - |
| Jun 18, 1997 | Accounts & Dividend | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|
19 Apr 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyASTRAZENECA PHARMA INDIA LTD. 2CIN NO.L24231KA1979PLC003563 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY 000 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Manasa R Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Bhavana Agrawal Designation: Chief Financial Officer and Director EmailId: [email protected] Date: 19/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
16 Apr 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
As required under Regulation 49(10) of SEBI (LODR) Regulations, 2015, we furnish herewith a certificate issued by the Practising Company Secretary with regard to transfer of securities effected during the year ended March 31, 2024.
12 Apr 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
This is to certify that Integrated Registry Management Services Private Limited, are the Company''s RTA and that all activities are in relation to the share transfer are maintained by them. We are also attaching the certificate received from our RTA.
12 Apr 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith the Certificate dated April 5, 2024 issued by the RTA of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
08 Apr 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot
This is in reference to our letter dated March 6, 2024, enclosing therewith a Postal Ballot Notice dated February 8, 2024 seeking consent of the members of the Company through Special Resolution for appointment of Ms. Bhavana Agrawal (DIN: 10485441) as a Director and also as a Whole-time Director of the Company. In relation to the same, we are enclosing herewith the Voting results along with the Scrutinizer''s Report and the same are being placed on the Company''s website and website of National Securities Depository Limited.
08 Apr 2024
AstraZeneca, Daiichi drug gets broad tumor approval in US
The US Food and Drug Administration cleared the medicine for patients who have HER2-positive solid tumors that have spread or can't be removed with surgery, the company said. These patients have already received prior treatment and don't have any good alternatives.
08 Apr 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Summary Of Proceedings Of 44Th Annual General Meeting
In furtherance to your email dated April 6, 2024 and the enclosed summary of proceedings of 44th Annual General Meeting held on August 14, 2023, we wish to inform that that the 44th Annual General Meeting commenced at 3:00 PM and concluded at 4:45 PM (IST).
05 Apr 2024
AstraZeneca Says Key Lung Cancer Drug Improved Survival
Lung cancer is the leading cause of cancer death among men and women, accounting for about 20% of all cancer deaths.
26 Mar 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015
This is to inform that AstraZeneca Pharma India Limited has received permission to import for sale and distribution of Trastuzumab deruxtecan lyophilized powder for concentrate for solution for infusion 100mg (Enhertu) from Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India for the attached additional indications.
25 Mar 2024
AstraZeneca Pharma India appoints Vinay Sharma as business unit head
Currently, Sharma is a part of the Philippines country leadership team as Business Unit Head Respiratory and Immunology
